Pre-Clinical in Vitro and in Vivo Evidence for Plausible Mechanisms Underlying the Risk of Cancer Associated with Insulin and Insulin Analogues.
Conclusion: In general many studies on pre-clinical in vitro and in vivo evidence for plausible mechanisms underlying the risk of cancer associated with insulin and insulin analogues exist. However, the level of evidence or a causal association between insulin and insulin analogues and cancer is low.
PMID: 24215309 [PubMed - as supplied by publisher] (Source: Current Drug Safety)
Source: Current Drug Safety - November 7, 2013 Category: Drugs & Pharmacology Authors: Vestergaard P, Starup-Linde J Tags: Curr Drug Saf Source Type: research
Mylan, Biocon in deal on insulin products
Mylan and Biocon Ltd. are in a partnership to develop and commercialize three generic insulin analog products.
Financial terms of the profit-sharing deal weren't disclosed. But Mylan will be able to develop Glargine, the generic version of Sanofi's Lantus; Lispro, the generic version of Eli Lilly's Humalog; and Aspart, the generic version of Nov Nordisk's NovoLog. The rights are for the U.S., Canada, the European Union and elsewhere.
The worldwide sales of the three are $11.5 billion in 2012, Mylan… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 14, 2013 Category: Pharmaceuticals Source Type: research
